NCT05293626: An ongoing trial by Neurophth Therapeutics Inc
This trial is ongoing. It must report results 7 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05293626 |
|---|---|
| Title | A Phase 1/2, Single-Arm, Open-Label, Dose-Finding Clinical Trial to Evaluate the Safety and Efficacy of Gene Therapy for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 22, 2023 |
| Completion date | July 31, 2025 |
| Required reporting date | July 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |